Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome.

Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, Coppola C, Chanana AM, Marji J, Bickers DR, Epstein EH Jr.

N Engl J Med. 2012 Jun 7;366(23):2180-8. doi: 10.1056/NEJMoa1113538.

2.

Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.

Cirrone F, Harris CS.

Clin Ther. 2012 Oct;34(10):2039-50. doi: 10.1016/j.clinthera.2012.08.011. Epub 2012 Oct 1. Review.

PMID:
23036338
3.

Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.

Proctor AE, Thompson LA, O'Bryant CL.

Ann Pharmacother. 2014 Jan;48(1):99-106. doi: 10.1177/1060028013506696. Epub 2013 Oct 15. Review.

PMID:
24259609
4.

Targeting the hedgehog pathway to treat basal cell carcinoma.

Geeraert P, Williams JS, Brownell I.

J Drugs Dermatol. 2013 May;12(5):519-23. Review.

PMID:
23652945
5.

Vismodegib in basal cell carcinoma.

Amaria RN, Bowles DW, Lewis KD, Jimeno A.

Drugs Today (Barc). 2012 Jul;48(7):459-67. doi: 10.1358/dot.2012.48.7.1808490. Review.

PMID:
22844657
6.

Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma.

Fife K, Herd R, Lalondrelle S, Plummer R, Strong A, Jones S, Lear JT.

Future Oncol. 2017 Jan;13(2):175-184. Epub 2016 Sep 19. Review.

PMID:
27640448
7.

A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.

Erdem GU, Sendur MA, Ozdemir NY, Yazıcı O, Zengin N.

Curr Med Res Opin. 2015 Apr;31(4):743-56. doi: 10.1185/03007995.2015.1018988. Epub 2015 Mar 17. Review.

PMID:
25690490
8.

Vismodegib: a hedgehog pathway inhibitor for locally advanced and metastatic basal cell carcinomas.

Sobanko JF, Okman J, Miller C.

J Drugs Dermatol. 2013 Oct;12(10 Suppl):s154-5. Review.

PMID:
24085062
9.

Vismodegib: a review.

Ruiz-Salas V, Alegre M, López-Ferrer A, Garcés JR.

Actas Dermosifiliogr. 2014 Oct;105(8):744-51. doi: 10.1016/j.ad.2013.09.012. Epub 2013 Dec 18. Review. English, Spanish.

PMID:
24359667
10.

Current landscape for treatment of advanced basal cell carcinoma.

Foley P.

Australas J Dermatol. 2015 Mar;56 Suppl 1:1-7. doi: 10.1111/ajd.12319. Review.

PMID:
25715811
11.

Efficacy and safety of vismodegib : a new therapeutic agent in the treatment of basal cell carcinoma.

Lyons TG, O'Kane GM, Kelly CM.

Expert Opin Drug Saf. 2014 Aug;13(8):1125-32. doi: 10.1517/14740338.2014.939952. Review.

PMID:
25033383
12.

Treatment of margin positive basal cell carcinoma with vismodegib: case report and consideration of treatment options and their implications.

Bayers S, Kapp DL, Beer KR, Slavin B.

J Drugs Dermatol. 2013 Oct;12(10 Suppl):s147-50. Review.

PMID:
24085060
14.

Vismodegib for the treatment of basal cell skin cancer.

Poggi L, Kolesar JM.

Am J Health Syst Pharm. 2013 Jun 15;70(12):1033-8. doi: 10.2146/ajhp120311. Review.

PMID:
23719880
15.
16.

Vismodegib.

Meiss F, Zeiser R.

Recent Results Cancer Res. 2014;201:405-17. doi: 10.1007/978-3-642-54490-3_25. Review.

PMID:
24756807
17.

Cholestatic hepatic injury associated with vismodegib, aspirin, and naproxen use: a case study and review of vismodegib safety.

Ash MM, Jolly PS.

Int J Dermatol. 2015 Mar;54(3):370-4. doi: 10.1111/ijd.12543. Epub 2014 Jul 11. Review.

PMID:
25039741
18.

Hedgehog- and mTOR-targeted therapies for advanced basal cell carcinomas.

Piérard-Franchimont C, Hermanns-Lê T, Paquet P, Herfs M, Delvenne P, Piérard GE.

Future Oncol. 2015 Nov;11(22):2997-3002. doi: 10.2217/fon.15.181. Epub 2015 Oct 5. Review.

PMID:
26437034
19.

Emerging treatments and signaling pathway inhibitors.

Tang JY, Marghoob AA.

Semin Cutan Med Surg. 2011 Dec;30(4 Suppl):S14-8. doi: 10.1016/j.sder.2011.11.002. Review.

PMID:
22177102
20.

Vismodegib: in locally advanced or metastatic basal cell carcinoma.

Keating GM.

Drugs. 2012 Jul 30;72(11):1535-41. doi: 10.2165/11209590-000000000-00000. Review.

PMID:
22788238

Supplemental Content

Support Center